Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

[1]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[2]  F. De Vita,et al.  Anti‐epidermal growth factor receptor monoclonal antibodies in cancer therapy , 2009, Clinical and experimental immunology.

[3]  A. Bardelli,et al.  Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) , 2009, British Journal of Cancer.

[4]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Y. Bang,et al.  Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer , 2009, British Journal of Cancer.

[6]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[7]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[8]  J. Zaluski,et al.  Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Hayao Nakanishi,et al.  Interleukin‐2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor‐overexpressing gastric cancer xenografts through antibody‐dependent cellular cytotoxicity , 2008, Cancer science.

[10]  T. Joh,et al.  Suppression of proHB-EGF Carboxy-Terminal Fragment Nuclear Translocation: A New Molecular Target Therapy for Gastric Cancer , 2008, Clinical Cancer Research.

[11]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Bokemeyer,et al.  Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[14]  F. Lordick,et al.  Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Fenoglio-Preiser,et al.  Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[20]  F. Lordick,et al.  Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer , 2005, British Journal of Cancer.

[21]  J. Zaluski,et al.  Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[23]  J. Nährig,et al.  Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system , 2004, Modern Pathology.

[24]  Suk Woo Nam,et al.  BRAF and KRAS mutations in stomach cancer , 2003, Oncogene.

[25]  Jae-Hyun Park,et al.  Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers , 2003, Human Genetics.

[26]  R. Goldbohm,et al.  K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. , 2003, Carcinogenesis.

[27]  E. Van Cutsem,et al.  Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[29]  T. Hickish,et al.  Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial , 1999, British Journal of Cancer.

[30]  D. Hicklin,et al.  Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. , 2009, International journal of oncology.

[31]  W. Budach,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[32]  R. Berardi,et al.  Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  J. Ajani,et al.  Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group , 2006 .

[34]  M. Stratton,et al.  Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability , 2004, International journal of cancer.

[35]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.